GIA
MTNB icon

Gladstone Institutional Advisory’s Matinas BioPharma MTNB Stock Holding History

Gladstone Institutional Advisory’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-200
Closed -$6K – 282
2019
Q3 		$6K Buy
+200
New +$7.23K ﹤0.01% 282

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Gladstone Institutional Advisory's MTNB Position: Q4 2019 in Review

Gladstone Institutional Advisory sold out of Matinas BioPharma (MTNB) in Q4 2019, closing a stake of 200 shares — an estimated $6K sold.

Gladstone Institutional Advisory first reported a position in MTNB in Q3 2019 and held it in 1 quarter. The position peaked at $6K in Q3 2019. 64 funds tracked by Wall St. Rank hold MTNB as of Q4 2019.

  • Gladstone Institutional Advisory reported no remaining Matinas BioPharma position as of Q4 2019 after selling out during the quarter.
  • Gladstone Institutional Advisory sold 200 Matinas BioPharma shares in Q4 2019, an estimated $6K.
  • Gladstone Institutional Advisory first reported a position in Matinas BioPharma in Q3 2019 and held it in 1 quarter.
  • Gladstone Institutional Advisory's Matinas BioPharma position peaked at $6K in Q3 2019.
  • 64 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2019.

Based on Gladstone Institutional Advisory's 13F filing for Q4 2019, filed 12 Feb 2020.